Comparison of Myelotoxicity and Nephrotoxicity Between Daily Low-Dose Cisplatin With Concurrent Radiation and Cyclic High-Dose Cisplatin in Non-Small Cell Lung Cancer Patients

• Ngā kaituhi matua: Zulfan Zazuli (Author), Renate Kos (Author), Joris D. Veltman (Author), Wilma Uyterlinde (Author), Cristina Longo (Author), Paul Baas (Author), Rosalinde Masereeuw (Author), Susanne J. H. Vijverberg (Author), Anke-Hilse Ma (Author)
• Hōputu: Pukapuka
• I whakaputaina: Frontiers Media S.A., 2020-06-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

AimAntineoplastic effect of cisplatin, the first line treatment in non-small cell lung cancer (NSCLC), is hindered by its nephrotoxicity and myelotoxicity. Both low-dose and high-dose regimens are used in the management of NSCLC. The aim of this study is to assess the risk on myelotoxicity and nephr...